Human Germline CRISPR-Cas Modification: Toward a Regulatory Framework

CRISPR germline editing therapies (CGETs) hold unprecedented potential to eradicate hereditary disorders. However, the prospect of altering the human germline has sparked a debate over the safety, efficacy, and morality of CGETs, triggering a funding moratorium by the NIH. There is an urgent need fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Evitt, Niklaus H., Mascharak, Shamik, Altman, Russ B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2015
Materias:
Target Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4699477/
https://www.ncbi.nlm.nih.gov/pubmed/26632357
http://dx.doi.org/10.1080/15265161.2015.1104160

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4699477/
https://www.ncbi.nlm.nih.gov/pubmed/26632357
http://dx.doi.org/10.1080/15265161.2015.1104160

Ejemplares similares